Renin‐angiotensin‐aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease-Reference-Cited by-同舟云学术

Renin‐angiotensin‐aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease

Published:2021-09-22 Issue:12 Volume:41 Page:988-997
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Sud Maneesh¹²³⁴^ORCID,Ko Dennis T.¹²³⁴,Chong Alice³,Koh Maria³,Azizi Paymon M.²³⁴,Austin Peter C.²³,Stukel Thérèse A.²³,Jackevicius Cynthia A.²³⁵⁶^ORCID

Affiliation:

1. Schulich Heart Program Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada

2. Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada

3. ICES Toronto ON Canada

4. Temerty Faculty of Medicine University of Toronto Toronto ON Canada

5. Western University of Health Services Pomona California USA

6. VA Greater Los Angeles Healthcare System Los Angeles California USA

Funder

Canadian Institutes of Health Research

Heart and Stroke Foundation of Canada

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2624

Reference33 articles.

1. Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease

2. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons;Fihn SD;J Am Coll Cardiol,2012

3. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

4. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients;Heart Outcomes Prevention Evaluation Study Investigators;N Engl J Med,2000

5. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‐blind, placebo‐controlled, multicentre trial (the EUROPA study);Fox KM;Lancet,2003

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines;Circulation;2023-08-29

2. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease;Journal of the American College of Cardiology;2023-08

3. Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome;DAHUDER Medical Journal;2022-07-27

4. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers;Diabetes & Metabolism;2022-03

5. Exploring the frontier of cardiovascular pharmacotherapy;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2021-12